272 research outputs found
Supplementary_Material - How resources determine pulmonary rehabilitation programs: A survey among Belgian chest physicians
No full textSupplementary_Material for How resources determine pulmonary rehabilitation programs: A survey among Belgian chest physicians by Wim Janssens, Jean-Louis Corhay, Peter Bogaerts, Eric Derom, Nicolas Frusch, Delphine Nguyen Dang, Jesabelle Kibanda, David Ruttens, Lisa Thyrion, Thierry Troosters, Eric Marchand in Chronic Respiratory Disease</p
Supplementary_Material - How resources determine pulmonary rehabilitation programs: A survey among Belgian chest physicians
No full textSupplementary_Material for How resources determine pulmonary rehabilitation programs: A survey among Belgian chest physicians by Wim Janssens, Jean-Louis Corhay, Peter Bogaerts, Eric Derom, Nicolas Frusch, Delphine Nguyen Dang, Jesabelle Kibanda, David Ruttens, Lisa Thyrion, Thierry Troosters, Eric Marchand in Chronic Respiratory DiseaseSupplementary_Material for How resources determine pulmonary rehabilitation programs: A survey among Belgian chest physicians by Wim Janssens, Jean-Louis Corhay, Peter Bogaerts, Eric Derom, Nicolas Frusch, Delphine Nguyen Dang, Jesabelle Kibanda, David Ruttens, Lisa Thyrion, Thierry Troosters, Eric Marchand in Chronic Respiratory Disease</p
Autonomic (dys)function in patients with chronic obstructive pulmonary disease : evidence and non-pharmacological interventions
No full textLaunching Global Lung Function Initiative reference values in Belgium : tips and tricks
No full textsponsorship: E. Derom has nothing to disclose concerning the submitted manuscript, but received financial support from AstraZeneca, Chiesi and Boehringer Ingeheim to attend ERS and ATS congresses, and participated in national advisory boards for AstraZeneca, Boehringer, GSK, Novartis and Chiesi. W. Janssens reports receiving grants from GSK, AstraZeneca, Boehringer and Chiesi, outside the submitted work. (AstraZeneca, Chiesi, Boehringer Ingeheim)status: Publishe
Symphonic music in occupied Belgium (1940–1944) : the role of ‘German-friendly’ music societies
No full textThis chapter describes how the Nazi administration implemented the political exploitation of classical music in occupied Belgium, a country where German and Latin cultures had co-existed for centuries. The main focus is that of concert life in three major cities of Brussels, Antwerp and Ghent where newly established music associations controlled by radical Flemish nationalists and supported by the occupation forces, organised their own seasons of concerts as alternatives to the pre-existing mainly French-orientated music societies. The initial impetus for this development was to promote Flemish composers and thereby reduce the influence of French music upon Belgian musical life. In 1940 and 1941, the main repertoire presented by the ‘German-friendly’ music societies consisted of German and Flemish music, French music being completely marginalised. Yet by 1942, composers rarely played in Belgium, such as Bruckner, Reger and Pfitzner, and new German music approved by the Third Reich and premiered in Germany were increasingly programmed, ironically at the expense of Flemish music. A central focus is the role played by these new musical societies in blindly following Nazi cultural policies and thereby supporting the occupiers’ ultimate goal of incorporating Flanders into the German Reich
Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
No full textEric Derom, Guy G Brusselle, Guy F Joos Department of Respiratory Medicine, Ghent University Hospital, Ghent, BelgiumAbstract: Tiotropium–olodaterol, formulated in the Respimat soft-mist inhaler, is an inhaled fixed-dose combination (FDC) of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA), commercialized under the name of Spiolto or Stiolto. The efficacy of tiotropium–olodaterol 5–5 µg once daily in adult patients with COPD was documented in eleven large, multicenter trials of up to 52 weeks duration. Tiotropium–olodaterol 5–5 µg not only improved spirometric values to a significantly greater extent than placebo but also resulted in statistically significant beneficial effects on dyspnea, markers of hyperinflation, use of rescue medication, health-related quality of life, and exercise endurance. Improvements exceeded the minimal clinically important difference (MCID) for forced expiratory volume in 1 second (FEV1), dyspnea, and quality of life. Differences between tiotropium–olodaterol 5–5 µg and the respective monocomponents were statistically significant for FEV1, dyspnea, markers of hyperinflation, use of rescue medication, and health-related quality of life, but did not reach the MCID. However, dual bronchodilatation significantly increased the number of patients who exceeded the MCID for dyspnea and quality of life. Moreover, tiotropium–olodaterol 5–5 µg was significantly more effective than salmeterol–fluticasone (FDC) twice daily at improving pulmonary function. Differences between tiotropium–olodaterol and other LAMA/LABA FDCs were not observed for FEV1 or other efficacy markers. Therefore, tiotropium–olodaterol is a valuable option in the treatment of COPD patients who remain symptomatic under monotherapy. Keywords: COPD, bronchodilatation, dyspnea, exacerbation, exercise tolerance, LABA, LAMA, spirometr
Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice
No full textDidier Cataldo,1 Eric Derom,2 Giuseppe Liistro,3 Eric Marchand,4,5 Vincent Ninane,6 Rudi Peché7 Hans Slabbynck,8 Walter Vincken,9 Wim Janssens10 1Department of Respiratory Medicine, Centre Hospitalier Universitaire de Liège (CHU) and University of Liège, Liège, Belgium; 2Department of Respiratory Medicine, Ghent University Hospital, Gent, Belgium; 3Department of Respiratory Medicine, University Hospitals Saint-Luc, Brussels, Belgium; 4Department of Respiratory Medicine, University Hospital UCL Namur, Yvoir, Belgium; 5URPhyM, University of Namur, Namur, Belgium; 6Department of Respiratory Medicine, University Hospital Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium; 7Department of Respiratory Medicine, University Hospital Vésale, Montigny-le-Tilleul, Belgium; 8Department of Respiratory Medicine, ZNA Middelheim, Antwerpen, Belgium; 9Respiratory Division, University Hospital Brussels (UZ Brussel), Vrije Universiteit Brussel, Brussels, Belgium; 10Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium Abstract: Evidence and guidelines are becoming increasingly clear about imbalance between the risks and benefits of inhaled corticosteroids (ICSs) in patients with COPD. While selected patients may benefit from ICS-containing regimens, ICSs are often inappropriately prescribed with – according to Belgian market research data – up to 70% of patients in current practice receiving ICSs, usually as a fixed combination with a long-acting β2-adrenoreceptor agonist. Studies and recommendations support withdrawal of ICSs in a large group of patients with COPD. However, historical habits appear difficult to change even in the light of recent scientific evidence. We have built a collaborative educational platform with chest physicians and primary care physicians to increase awareness and provide guidance and support in this matter. Keywords: COPD, exacerbation, withdrawal, inhaled steroids, systematic review, educatio
- …
